D-MPH in the Treatment of Fatigue and Neurobehavioral Function Related to Chemotherapy in Adult Cancer Patients

Phase 2

Completed

• Conditions: Fatigue; Neoplasms

• Registration Number: NCT00047476
• Lead Sponsor: Celgene Corporation

Brief Summary

To evaluate the efficacy of dexmethylphenidate (d-MPH) in the treatment of chemotherapy-related fatigue in adult cancer subjects.

Detailed Description

Not available

Study Timeline

• Study Start: 2002-06
• Study First Submitted: 2002-10-08
• Study First Submitted QC: 2002-10-08
• Study First Posted: 2002-10-09
• Study Completion: 2004-03
• Status Verified: 2004-05
• Last Update Submitted: 2005-06-23
• Last Update Posted: 2005-06-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 160

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Trial Locations

Locations (21)

Cooper Green Hospital, Jefferson Clinic; 🇺🇸 Birmingham, Alabama, United States

University of Alabama Palliative Care Institute; 🇺🇸 Birmingham, Alabama, United States

Peak Performance Wellness; 🇺🇸 Flagstaff, Arizona, United States

Arizona Clinical Research Center; 🇺🇸 Tucson, Arizona, United States

Alta Bates Comprehensive Cancer Center; 🇺🇸 Berkeley, California, United States

California Cancer Care Inc; 🇺🇸 Greenbrae, California, United States

Clinical Trials and Research Associates; 🇺🇸 Montebello, California, United States

Comprehensive Cancer Centers of the Desert; 🇺🇸 Palm Springs, California, United States

Comprehensive Cancer Center; 🇺🇸 Boca Raton, Florida, United States

Osler Clinical Research/Osler Medical Inc; 🇺🇸 Melbourne, Florida, United States

Scroll for more (11 remaining)